The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy

Immunotherapy. 2018 Sep;10(12):1041-1045. doi: 10.2217/imt-2018-0027.

Authors

Caterina Fumagalli¹, Elena Guerini-Rocco^{1

2}, Davide Vacirca¹, Antonio Passaro³, Filippo de Marinis³, Massimo Barberis¹

Affiliations

¹ Division of Pathology & Laboratory Medicine, European Institute of Oncology, Via Ripamonti 451, 20141 Milan, Italy.
² Department of Oncology & Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.
³ Division of Thoracic Oncology, European Institute of Oncology, Via Ripamonti 451, 20141 Milan, Italy.

PMID: 30185137
DOI: 10.2217/imt-2018-0027

No abstract available

Keywords: EGFR; immune microenvironment; resistance.

Publication types

Case Reports

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
B7-H1 Antigen / metabolism
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / immunology*
Disease Progression
Drug Resistance, Neoplasm / genetics
ErbB Receptors / genetics
Female
High-Throughput Nucleotide Sequencing
Humans
Immunity / genetics
Lung Neoplasms / drug therapy
Lung Neoplasms / immunology*
Lymphocytes, Tumor-Infiltrating / immunology*
Male
Middle Aged
Mutation / genetics
Neoplasm Staging
Protein Kinase Inhibitors / therapeutic use*
Tumor Microenvironment

Substances

B7-H1 Antigen
CD274 protein, human
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors